Related Experiment Video

Updated: May 26, 2026

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

Denosumab in patients with cancer-a surgical strike against the osteoclast

Janet E Brown1, Robert E Coleman

  • 1Cancer Research UK Center, St. James's Hospital, Leeds LS9 7TF, UK.

Nature Reviews. Clinical Oncology
|January 11, 2012
PubMed

Insights

Denosumab, a RANKL inhibitor, effectively prevents bone loss and fractures in cancer patients and osteoporosis. It shows superior efficacy over bisphosphonates in reducing skeletal morbidity from bone metastases.

Area of Science:

  • Oncology
  • Bone Biology
  • Pharmacology

Background:

  • Bone turnover is regulated by molecular pathways, including receptor activator of nuclear factor-κB ligand (RANKL).
  • RANKL is crucial for osteoclast formation, function, and survival.
  • Dysregulation of bone turnover contributes to skeletal complications in cancer and osteoporosis.

Purpose of the Study:

  • To review the role of denosumab in maintaining bone health in cancer patients.
  • To compare the efficacy of denosumab with bisphosphonates in managing bone metastases.
  • To discuss factors influencing treatment choices between denosumab and bisphosphonates.

Main Methods:

  • Review of large phase III studies and clinical trials.
  • Analysis of denosumab's efficacy in bone metastasis and giant-cell tumors of the bone.
  • Exploration of denosumab's impact on bone metastasis delay and adjuvant settings.

Main Results:

  • Denosumab inhibits RANKL, preventing bone loss and reducing fractures.
  • Denosumab is more effective than zoledronic acid in reducing skeletal morbidity in bone metastases.
  • Denosumab shows activity in giant-cell tumors and can delay bone metastasis in prostate cancer.

Conclusions:

  • Denosumab is a valuable therapeutic agent for maintaining bone health in oncology.
  • Denosumab offers advantages over bisphosphonates for managing skeletal-related events.
  • Clinical decisions should consider patient-specific factors when choosing between denosumab and bisphosphonates.

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.